Split-type electrochemiluminescent gene assay platform based on gold nanocluster probe for human papillomavirus diagnosis
Split-type electrochemiluminescent gene assay platform based on gold nanocluster probe for human papillomavirus diagnosis
复制标题
基于金纳米簇探针的分体式电化学发光基因检测平台用于人乳头瘤病毒诊断
DOI：
10.1016/j.bios.2021.113044
复制
发表时间：
2021-02-05
影响因子：
12.6
通讯作者：
Peng, Huaping
中科院分区：
文献类型：
--
作者：
Hong, Guolin;Zou, Zhiyan;Peng, Huaping
宫颈癌是由人乳头瘤病毒（HPV）引起的一种恶性肿瘤。HPV16 E7的检测对该病的早期诊断和治疗具有重要意义。在这里，一个新的和高性能的Au纳米簇（AuNC）探针为基础的分裂型电致发光（ECL）检测平台已被建立来检测这些癌基因，其中核酸杂交检测和ECL测量独立进行。该方法结合了上级磁性纳米珠富集分离技术、特异性核酸杂交技术和高效AuNC探针ECL策略，显示出优异的优势。首先，分体式ECL传感平台可以有效避免来自生物样品的干扰，并充分利用AuNC探针的ECL效率。此外，HPV DNA的病毒敏感性测定可以在没有任何复杂的核酸扩增技术的情况下实现。利用分裂型检测的上述优点，ECL DNA传感器实现了理想的低检测6.8 aM和宽动态范围桥接10个数量级的HPV 16 E7。此外，该策略具有良好的和强大的特异性，高灵敏度和良好的选择性，可以检测人类样本中的HPV 16 E7 DNA，这与FDA批准的方法（Hybrid capture 2，HC2）表现出很大的一致性。因此，本工作提出了一种简便可靠的分裂型ECL平台用于HPV诊断，并显示出对其他疾病的早期诊断的巨大潜力。
Persistent high-risk human papillomavirus (HPV) infection is the leading cause of cervical cancer. Efficient detection of HPV16 E7 is necessary for early diagnosis and cure of the disease. Here, a novel and high-performance Au nanocluster (AuNC) probe-based split-type electrochemiluminescent (ECL) assay platform has been established to detect these oncogenes, in which the nucleic acid hybridization assay and the ECL measurements are performed independently. The proposed approach combines superior magnetic nanobead enrichment and separation technology, specific nucleic acid hybridization technology, and high-efficiency AuNC probe ECL strategy, and shows excellent advantages. First, the split-type ECL sensing platform can effectively avoid interference from biological samples and adequately uses the ECL efficiency of the AuNC probe. Furthermore, the ultrahigh sensitivity assay of HPV DNA can be achieved without any complex nucleic acid amplification technique. Taking advantage of the above merits of split-type detection, the ECL DNA sensor achieved ideal low detection of 6.8 aM and a wide dynamic range bridging 10 orders of magnitude HPV16 E7. Furthermore, together with its favorable and powerful specificity, high sensitivity, and good selectivity, this strategy could detect HPV16 E7 DNA in human samples, which showed great consistency with the FDA-approved approach (Hybrid capture 2, HC2). Therefore, this work proposes a facile and reliable split-type ECL platform for HPV diagnosis and shows great potential for the early diagnosis of other diseases.